A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses (SAD) of ABBV-243 in Healthy Adult Subjects and a Single Dose in Healthy Asian Adult Subjects

Summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in healthy adult participants (Part 1), and a single intravenous (IV) dose in healthy Asian adult volunteers (Part 2 There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Eligibility

Age range

18–60 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  ABBV-243

  Intravenous (IV) Infusion

• Drug
  Placebo

  Intravenous (IV) Infusion

• Drug
  ABBV-243

  Subcutaneous (SC) Injection

• Drug
  Placebo

  Subcutaneous (SC) Injection

Location